Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty
Osteoarthritis, Knee
About this trial
This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Knee arthroplasty, Exparel, Bupivacaine liposome, Total knee replacement, Pain control
Eligibility Criteria
Inclusion Criteria:
- Patients must be over the age of 18
- Patients must have a preoperative diagnosis of osteoarthritis of the knee requiring total knee arthroplasty
Exclusion Criteria:
- Allergy to ExparelTM or certain other local anesthetic agents
- Pregnant females or females who think they may become pregnant
- Markedly abnormal kidney function or renal disease
- History of substance abuse
- History of chronic pain requiring medication
- Had a previous total knee arthroplasty on the same knee which is being replaced (revision total knee arthroplasty)
- Had a previous partial knee arthroplasty, such as a unicompartmental knee arthroplasty on the same knee (also a revision total knee arthroplasty)
Sites / Locations
- Broward Health Sports Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intracapsular Injection
Periarticular Injection
Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.